MedTrace Logo

Clinical Translation of a Novel FAPI Dimer [68Ga]Ga-LNC1013

NCT06159049 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2023-12-06

No results posted yet for this study

Summary

Fibroblast activation protein (FAP) emerges as a highly promising target for cancer diagnostic imaging and targeted radionuclide therapy. To exploit the therapeutic potential of current FAP inhibitors (FAPIs), this study presented the design and synthesis of a series of FAPI dimers to increase tumor uptake and retention. Preclinical evaluation and a pilot clinical PET imaging study were conducted to screen the lead compound with the potential for radionuclide therapy.

Conditions

Interventions

DIAGNOSTIC_TEST

68Ga-FAPI dimer(68Ga-LNC1013)

68Ga-LNC1013 was evaluated in a pilot clinical PET imaging study involving seven patients with gastrointestinal cancer.

Sponsors & Collaborators

  • Xiangya Hospital of Central South University

    lead OTHER

Principal Investigators

  • Shuo Hu, Dr · Xiangya Hospital, Central South University, Changsha, P.R. China

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-21
Primary Completion
2022-07-21
Completion
2022-11-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06159049 on ClinicalTrials.gov